Drugs in development for tuberculosis

Drugs

Volumn 70, Issue 17, 2010, Pages 2201-2214

  Ginsberg, Ann M ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

AZD 5847; Gatifloxacin; Linezolid; Metronidazole; Moxifloxacin; OPC 67683; PA 824; PNU 100480; Research and development; Rifampicin; Rifapentine; SQ 109; Sudoterb; TMC 207; Tuberculosis.

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AZD 5847; GATIFLOXACIN; LINEZOLID; LL 3858; METRONIDAZOLE; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PNU 100480; RIFAMPICIN; RIFAPENTINE; SUDOTERB; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESEARCH; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS;

ADAMANTANE; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; ETHYLENEDIAMINES; HUMANS; QUINOLINES; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 78449274705     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11538170-000000000-00000     Document Type: Review

References (32)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva: WHO, 2009. Report no.: WHO/HTM/TB/2009.426
2. World Health Organization. Global tuberculosis control 2009. Geneva: WHO, 2009. Report no.: WHO/HTM/ TB/2009.411
3. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010 May 15; 50 Suppl. 3: S223-300
4. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO, 2010. Report no.: WHO/HTM/TB/2010.3
5. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-5
6. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-79
7. van Niekerk C, Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: dowehave what it takes? Int J Tuberc Lung Dis 2009; 13: 1367-72
8. Andries K, Verhasselt P, Guillemont J, et al. A diarylqui-noline drug active on the ATP synthase of Mycobacter-ium tuberculosis. Science 2005; 307: 223-7 10.
9. Koul A, Dendouga N, Vergauwen K, et al. Diarylquino-lines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
10. Huitric E, Verhasselt P, Andries K, et al. In vitroantimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51: 4202-4.
11. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al.Selectivity of TMC207 towards mycobacterial ATP syn-thase compared with that towards the eukaryotic homo-logue. Antimicrob Agents Chemother 2009 Mar; 53 (3): 1290-2.
12. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolinesare bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-80.
13. Ibrahim M, Andries K, Lounis N, et al. Synergistic activityof R207910 combined with pyrazinamide against mu-rine tuberculosis. Antimicrob Agents Chemother 2007; 51: 1011-5.
14. Lounis N, Veziris N, Chauffour A, et al. Combinationsof R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006; 50: 3543-7.
15. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidalactivity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Anti-microb Agents Chemother 2008; 52: 2831-5.
16. Diacon AH, Pym A, Grobusch M, et al. The diarylquino-line TMC207 for multidrug resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
17. Diacon AH, Pym A, Grobusch MP, et al. Final resultsfrom stage 1 of a double-blind, placebo-controlled trial with TMC207 in patients with multi-drug resistant (MDR) tuberculosis (TB) [abstract no. L1-521a]. Inter-science Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12-15; Boston (MA).
18. Reddy VM, Einck L, Andries K, et al. In vitro interactionsbetween new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010 Jul; 54 (7): 2840-6.
19. Lupin Limited. A phase IIa, open label study to determinethe EBA, extended EBA and pharmacokinetic study of LL3858 for the treatment of newly diagnosed sputum smear-positive pulmonary TB [online]. Available from URL http://www.newtbdrugs.org/project.php?id=155 [Accessed 2010 Jun 28].
20. Deidda D, Lampis G, Fioravanti R, et al. Bactericidalactivities of the pyrrole derivative BM212 against multi-drug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998; 2: 3035-7.
21. Arora SK, Sinha N, Sinha RK, et al. Synthesis and in vitroanti- mycobacterial activity of a novel anti-TB composition LL4858 [abstract no. F-1115]. American Society for Microbiology: program and abstracts of the 44th Interscience Conference on Antimicrobial Agents andChemotherapy. Washington, DC: American Society for Microbiology, 2004: 212.
22. Sinha RK, Arora SK, Sinha N, et al. In vivo activity ofLL4858 against Mycobacterium tuberculosis [abstract no. F-1116]. American Society for Microbiology: program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2004: 212.
23. Protopopova M, Hanrahan C, Nikonenko B, et al. Identi-fication of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-74.
24. Boshoff HI, Myers TG, Copp BR, et al. The transcriptionalresponses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004; 279: 40174-84.
25. Horwith G, Einck L, Protopopova M, et al. Phase 1 safetyand pharmacokinetics of SQ109, a new diamine anti-tuberculosis drug [abstract]. 45th IDSA Annual Meeting; 2007 Oct 4-7; San Diego (CA).
26. Chen P, Gearhart J, Protopopova M, et al. Synergisticinteractions of SQ109, a new ethylene diamine, with frontline antitubercular drugs in vitro. J Antimicrob Chemo-ther 2006; 58: 332-7.
27. Nikonenko BV, Protopopova M, Samala R, et al. Drugtherapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51: 1563-5.
28. East African/British Medical Research Council. Controlledclinical trial of shortcourse (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-85.
29. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
30. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosingof rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4: e344.
31. Diacon AH, Patientia RF, Venter A, et al. Early bacter-icidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51: 2994-6.
32. Jindani A, Aber VR, Edwards EA, et al. The early bacter-icidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.